What Is Molecular Imaging?

Molecular imaging is a discipline that combines in vivo imaging technology with molecular biology to visualize, characterize, and quantify biological processes at the cellular and molecular level in living organisms. Rather than depicting anatomical structures, it identifies changes in the biochemistry and physiology of cells and tissues before those changes produce detectable structural alterations. The field draws on physics, chemistry, biology, and biomedical engineering, integrating radiotracer chemistry, detector hardware, image reconstruction algorithms, and computational analysis into a unified diagnostic framework.

The field emerged from nuclear medicine in the mid-twentieth century and expanded significantly with advances in positron emission tomography and the development of targeted imaging agents in the 1990s. Today it spans several distinct imaging modalities, each offering different trade-offs in spatial resolution, sensitivity, depth penetration, and the types of molecular targets accessible.

Radionuclide Imaging

Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are the two primary radionuclide imaging modalities in molecular imaging. PET works by detecting pairs of gamma rays emitted when a positron from a radioactive tracer annihilates with an electron in tissue, enabling whole-body mapping of molecular targets with picomolar sensitivity. SPECT uses gamma-emitting radionuclides such as technetium-99m and iodine-123, which are more widely available and less costly than PET isotopes, though at reduced spatial resolution. Both modalities depend on radiopharmaceuticals, compounds where a radionuclide is chemically attached to a biologically active molecule that concentrates in a specific tissue or binds a specific receptor. The design and synthesis of these radiopharmaceuticals is central to the field, as reviewed in research published by PMC/NIH on PET and SPECT radiopharmaceuticals.

Magnetic Resonance and Optical Methods

Magnetic resonance imaging contributes to molecular imaging through techniques such as MR spectroscopy and contrast-enhanced MRI using targeted probes, offering high spatial resolution and three-dimensional tissue contrast without ionizing radiation. Optical methods, including fluorescence imaging and bioluminescence imaging, track light-emitting proteins and dyes in preclinical models with high sensitivity, though optical approaches are limited in depth penetration and are primarily used in small-animal research rather than clinical practice. Combining modalities is common: PET/MRI systems, for example, capture functional metabolic data from PET simultaneously with the detailed soft-tissue contrast of MRI, as discussed in an overview of multimodal molecular imaging in Contrast Media and Molecular Imaging.

Imaging Agents and Target Specificity

The distinguishing feature of molecular imaging relative to conventional radiology is target specificity. Imaging agents are designed to bind particular molecular structures, including receptor proteins, enzyme active sites, transporter proteins, and metabolic substrates. The most widely used clinical agent, fluorodeoxyglucose (FDG), is a glucose analog that accumulates in tissues with elevated glucose metabolism, making it especially useful for identifying metabolically active tumors. Beyond FDG, a growing class of targeted probes addresses receptors in oncology, neurodegeneration, and cardiovascular pathology. The design principles and clinical performance of such probes are addressed in PMC/NIH research on PET and SPECT imaging of tumor biology.

Applications

Molecular imaging has applications in a wide range of fields, including:

• Oncology: detection, staging, and treatment response assessment for solid tumors and lymphomas
• Neurology: imaging of amyloid plaques, dopamine transporters, and neuroinflammation in Alzheimer's disease and Parkinson's disease
• Cardiovascular medicine: perfusion imaging, viability assessment, and characterization of atherosclerotic plaque
• Drug development: pharmacokinetic studies, receptor occupancy measurements, and target engagement confirmation in clinical trials
• Infectious disease and inflammation: tracking activated immune cells and sites of infection